---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-034560"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2023-07-26T23:59:59+00:00"
generated_at: "2026-06-13T02:26:17.353267+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa appoints former Momenta CSO Anthony Manning to Board

## Summary
- Board expanded from 8 to 9 directors; Dr. Manning fills newly created vacancy, effective July 25, 2023.
- He will serve as a Class II director until the 2026 annual meeting of stockholders.
- Board determined Manning is independent under Nasdaq listing standards.
- Manning was CSO at Momenta Pharma, which was acquired by J&J for $6.5B in 2020; expertise in autoimmune disease and drug discovery.
- He will receive cash and equity compensation per the company's non-employee director policy.

## SEC filing metadata
- accession: 0000950170-23-034560
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2023-07-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017023034560/0000950170-23-034560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017023034560/glue-20230726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-034560
- JSON: https://secwatch.observer/filing/0000950170-23-034560.json
- Plain text: https://secwatch.observer/filing/0000950170-23-034560.txt

## Key facts
- Executive change
  Anthony M. Manning was appointed as Director at Monte Rosa Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board appointed Anthony M. Manning, Ph.D. to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from eight (8) to nine (9) directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000095017023034560/0000950170-23-034560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.